Fedotova I B, Perepelkina O V, Nikolaev G M, Surina N M, Poletaeva I I
Faculty of Biology, M. V. Lomonosov Moscow State University, Moscow, Russia.
Bull Exp Biol Med. 2019 Aug;167(4):464-466. doi: 10.1007/s10517-019-04550-9. Epub 2019 Sep 6.
The anticonvulsant effect of ethosuximide (T-type calcium channel blocker) was evaluated in Krushinsky-Molodkina rats predisposed to audiogenic epilepsy. Ethosuximide given with drinking water (300 mg/kg/day) over 45 days slightly reduced proneness to audiogenic epilepsy and increased locomotor activity of the animals at the periphery of the open field. Neonatal administration of ethosuximide (3-4 mg per animal, from 2 to 10 days of life) insignificantly modulated the parameters of audiogenic epilepsy in these animals at the age of 1.5 months and reduced manifestation of audiogenic myoclonic convulsion that developed after long daily sound presentation started at the age of 3 months. The findings attested to a weak anticonvulsant effect of ethosuximide on tonic convulsions with its predominant effect on convulsions with forebrain focus location.
在易患听源性癫痫的克鲁申斯基-莫洛迪纳大鼠中评估了乙琥胺(T型钙通道阻滞剂)的抗惊厥作用。连续45天给动物饮用含乙琥胺的水(300毫克/千克/天),略微降低了动物对听源性癫痫的易感性,并增加了其在旷场周边区域的运动活性。新生期给予乙琥胺(每只动物3 - 4毫克,出生后2至10天)对1.5月龄动物听源性癫痫的参数影响不显著,但减少了3月龄开始长期每日声音刺激后出现的听源性肌阵挛惊厥的表现。这些结果证明乙琥胺对强直性惊厥的抗惊厥作用较弱,其主要作用于具有前脑病灶定位的惊厥。